Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System

This article was originally published in The Pink Sheet Daily

Executive Summary

The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.

You may also be interested in...

Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects

If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.

AIDS Advocates Push U.S. To Spend 50% Of Funds On Treatment

Advocates also are not sure whether to push for a long-term PEPFAR reauthorization; the U.S. expects to release a PEPFAR spending blueprint along with future goals shortly.

Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate

FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts